Pathogenesis of alopecia areata: immune mechanisms
INESSA SERBINA
Scientific consultant, TRICHOLOGY INSTITUTE ®
Сербина, И. М. Патогенез гнездной алопеции: иммунные механизмы / И. М. Сербина // Міжнар. мед. журн. – 2016. – № 4. – С.77–82.
Alopecia areata (AA) is a chronic inflammatory disease of the hair follicles with an unpredictable course: it can affect the scalp and/or hair on other areas, and can present as discrete patches of hair loss or as extensive, rapid total hair loss. Although AA is regarded as a relatively benign disease, hair loss leads to profound changes in the psychoemotional state, up to severe neurotic disorders and the formation of a pathological personality [1, 2].
The many hypotheses of the etiopathogenesis of AA, which include a wide range of initial factors, from the genetic basis of the immune system to the specificity of autoantigens and expression pathways and an understanding of the role of exogenous triggers, still do not provide exhaustive answers. It is assumed that the cytokine cascade and the lymphocytic arm of the immune system play an important role in the development and progression of this disease, leading to the formation of non-specific autoimmune inflammation [3–5]. The lack of a clear concept of the mechanisms of AA development explains the difficulty of finding a universal treatment for AA and justifies further study of the pathogenesis of the disease [6].
To this day the hair follicle remains a mystery for many researchers of hair physiology and morphology. This is due, above all, to the cyclical nature of growth and the action of «biological clocks» that determine the lifespan of a hair: the transition from rapid growth, pigmentation and formation of the hair shaft (anagen, the phase of active growth, which is divided into stages I–VI) to a short phase of organ involution (catagen) that triggers apoptosis. After catagen, and until the follicle re-enters anagen, the hair follicle goes through a period of relative rest (telogen). During the phase of controlled hair shedding (exogen) in healthy follicles, the old hair shaft usually falls out of the hair follicle after a new growth cycle has begun [5, 7]. In this way the total amount of hair cover is maintained. The cycling of these phases is precisely coordinated by the expression of hormones, cytokines, growth factors and their receptors, and is carefully regulated by endocrine, paracrine and autocrine pathways. Disruption of these finely tuned pathways can lead to the development of hair diseases [8].
AA is characterised by a disturbance of the hair follicle growth cycle: inflammatory cells (CD8+ T cells, mast cells, natural killer cells and others) attack only anagen hair follicles, which then prematurely enter the catagen phase [5, 9]. In the course of AA, exogen often occurs before anagen resumes, or, in the case of dystrophic anagen, a state called «kenogen» is observed, during which no visible hair fibres remain in the hair follicle. In essence, the areas of skin affected by AA are in a state of kenogen. Because of inflammation-induced dystrophy of the follicle, the hair shaft loses its ability to anchor firmly in the hair canal and falls out quickly; however, the hair follicle retains its capacity to regenerate and continues cyclical growth, since in AA, unlike in scarring alopecia, the follicular stem cells are usually not damaged [10]. Thus, hair loss in this disease is in principle reversible. Like most other autoimmune diseases, AA is a chronic relapsing inflammatory disease, which implies that the events provoking it are recurrent. At the same time, without a perifollicular infiltrate the hair does not fall out.
In both animal models of AA and humans, follicular inflammation consists mainly of CD4+ and CD8+ T cells, which clearly differ in their location. According to immunohistochemical analysis, activated CD8+ T cells can penetrate the hair follicles, whereas CD4+ T cells are located almost exclusively in the perifollicular area. Because most CD8+ T cells are cytotoxic, their presence in hair follicles can easily disrupt hair growth. In AA, activated cytotoxic T lymphocytes produce tumour necrosis factor α (TNF-α), Fas ligand and others. These molecules can potentially trigger apoptosis in the cells of the AA-affected hair follicle and, in general, disrupt its normal function [11, 12]. In rodent models of AA, depletion of CD8+ T cells can block the development of the disease. In the rat model, a reduction in the level of CD8+ T cells leads to a better hair growth response than depletion of CD4+ T cells, while an increase in the number of these cells leads to rapid recurrence of AA. Subcutaneous injections of activated CD8+ T cells stimulate sharp, localised hair loss exclusively at the injection site, whereas injections of CD4+ T cells do not cause local hair loss but ultimately promote systemic hair loss outside the immediate injection site [13]. These studies show that CD8+ cells provoke the destruction of the hair follicle and baldness, while CD4+ cells probably contribute to the development of AA by performing their classic «helper» role.
In the acute phase of AA, when CD8+ and CD4+ T lymphocytes penetrate the peribulbar area, cell density is an indicator of active progression of the disease [9, 14]. The combined effect of the primary inflammatory cell infiltrate may not change the hair growth cycle but will adversely affect the function of the hair follicles and will contribute to the state of «dystrophic anagen». And although the anagen phase is preserved, the inflammatory cell infiltration apparently impairs the ability of hair follicles to produce a hair fibre of adequate size or integrity. The exogen phase can occur as usual as a stage of the general hair growth cycle, but because of anagen dystrophy the hair that has fallen out is replaced by a fibre that does not maintain an equivalent hair cover [8].
An increase in the number of inflammatory cells around hair follicles can lead to their miniaturisation and a shortened hair growth cycle: rapid anagen and telogen phases (so-called «nanogen» hair follicles). As the disease progresses, up to 50% of the total number of hair follicles may gradually be in nanogen. The number of catagen/telogen follicles increases over time, and the more hair follicles enter the telogen phase, the smaller the volume of inflammation in the skin [2, 5].
In the chronic stage of AA, the most affected hair follicles are forced into prolonged telogen, with no attempts at re-entering anagen or growing new hair [5, 8]. At this stage the inflammation will, as a rule, be concentrated in the papillary layer of the dermis around the miniaturised hair follicles. On this basis AA is an inflammatory disease in which damage to the hair follicles is closely related to changes in the peri- and intrafollicular inflammatory infiltrate [3].
Although the AA phenotype is limited to the skin and its appendages, there is evidence that the disease mechanism and the «decision» to trigger it take place outside the skin, namely in the organs of the immune system. On antigenic stimulation, antigen-presenting cells of the skin normally migrate to lymphoid organs for immunological «training». Healthy skin does not contain lymphocytes in large numbers. The intense inflammatory infiltrate observed in association with AA suggests inward migration of activated cells from the central immune system. Experimental studies in mice confirm that blocking the skin-homing receptors of lymphocytes, or preventing the migration of antigen-presenting cells to the skin-draining lymph nodes, can prevent the development of AA and modify its progression [9]. Thus, in studying and elucidating the mechanisms of AA, the whole immune system of the body must be considered, not only that of the skin [15].
The research data obtained so far best describe AA as a disease «consistent» with an autoimmune mechanism. For indisputable evidence of autoimmunity, the primary target or targets attacked by the inflammatory cells must be characterised as an autoantigen or autoantigens derived from the follicular unit; however, this fact has yet to be proved [9, 12]. Nevertheless, at present the autoimmune scenario is the best explanation of the data obtained in clinical studies and observed in most patients with AA. The use of animal models has made it possible to obtain functional evidence demonstrating the dominance of the immune system in the pathogenesis of AA [13].
In the peripheral blood of some patients with AA, antibodies to thyroglobulin, parietal cells, adrenal cells and thyroid cells, antinuclear antibodies and rheumatoid factor have been found. These findings gave grounds for assuming a link between AA and autoimmune processes, but the first more specific indications of possible autoimmune mechanisms of the disease came with the emergence of facts about autoantibodies directly to hair follicles. The concentration of specific hair follicle IgG antibodies is increased in the peripheral blood of patients with AA. A recent study with ruxolitinib showed that the use of a JAK inhibitor, a drug for the treatment of myelofibrosis and rheumatoid arthritis, had a positive effect in AA. The fact that JAK inhibitors suppress cytokines relevant to many autoimmune diseases supports the theory that AA may have mechanisms similar to those of some other autoimmune diseases [5, 16].
The melanocyte and/or the anagen-associated autoantigen of hair follicles are most often considered as autoantigens. Follicle-specific hair proteins, such as hair-specific keratin 44/46 kDa and trichohyalin, are candidates for the role of autoantigens [9, 17]. However, the specificity of the targets of hair follicle autoantibodies can vary considerably among individuals with AA. In addition, studies using injections of autoantibodies in various models have not shown a significant pathogenic effect of the autoantibody. This suggests that the mechanism of AA is most likely cell-mediated rather than antibody-mediated. Nevertheless, the presence of hair follicle-specific autoantibodies indicates the activity of an autoimmune mechanism, and such antibodies may provide information about antigenic targets for T cells [9, 16].
The defining immunological feature of the hair follicle is that it creates an environment of relative immune privilege (IP), which as a rule makes an autoimmune attack on intrafollicularly expressed autoantigens unlikely [12, 18].
Researchers have long been interested in the ability of vital organs to survive for a long time while protected from inflammatory reactions and foreign invasion. In 1873 the Dutch ophthalmologist van Dooremaal described the phenomenon of IP using the long-term survival of mouse skin grafts transplanted into the anterior chamber of a dog's eye. Later, in 1948, the English biologist P. B. Medawar, who studied the fate of allogeneic skin grafts, established that, unlike grafts placed on other parts of the body (including the skin itself), allografts transplanted into the eyes and brain of a rabbit survived considerably longer [18].
IP is a term for the status of certain parts of the body in which the appearance of an antigen does not lead to an inflammatory immune response. Normally, tissue grafts are rejected because they become the target of an attack by the immune system. But in immune-privileged organs and tissues the graft rejection reaction does not occur for a long time. The best-known immune-privileged organs are the brain, the eyes, the embryo and the placenta. From an evolutionary point of view, these organs are vital for survival, and immune-mediated inflammation in any of them can have disastrous consequences [12, 18].
The process of IP is ensured by: blocking the spread of lymphatic vessels, which thereby limits their accessibility to elements of the immune system; a low level of expression of major histocompatibility complex class I, which T cells need in order to present autoantigens to CD8+ T lymphocytes; a small number of Langerhans cells or other antigen-presenting cells; inhibition of the activation of natural killer cells (NK cells); local production of cytokines that cause immunosuppression, for example transforming growth factor-β (TGF-β); the presence of neuropeptides; and constitutive expression of Fas ligand, which controls lymphoid cells expressing the Fas receptor [5, 9, 18].
By analogy, normal hair follicles do not express major histocompatibility complex (MHC) classes I and II, and there are only a few Langerhans cells around and inside hair follicles. Deactivation of MHC class I may reduce the risk that follicle-associated autoantigens will be presented to CD8+ T cells [9, 18]. However, such deactivation of the expression of MHC class I molecules entails the risk of an attack on hair follicles by NK cells, since they are programmed to recognise and eliminate MHC-I-negative cells. To reduce this risk, healthy hair follicles deactivate the expression of ligands that stimulate the activation of NK cell receptors (NKG2D), and secrete cytokines and growth factors that inhibit NK cells and have an immunosuppressive effect: melanocyte-stimulating hormone (α-MSH), TGF-β, insulin-like growth factor (IGF-1), indoleamine 2,3-dioxygenase (IDO), IL-10, and IK cytokine, which was isolated as a factor that suppresses IFN-γ-induced expression of MHC class II antigens (IK) [5, 12]. Researchers have demonstrated strong expression of the potent NK cell migration inhibitory factor (MIF), which prevents their accumulation around and inside hair follicles; taken together, these data support the involvement of IP in hair growth [14].
It has been suggested that the collapse of IP is the trigger for the onset of AA. Genetic predisposition and trigger factors can lead to deactivation of immunosuppressive cytokines [20]. A significant decrease in the level of two immunosuppressive agents that had not been detected before in AA has also been found: the lymphocyte proliferation inhibitor IDO and Red/IK. Importantly, a disturbance of the immunosuppressive environment even before the appearance of large-scale cellular infiltration in the perifollicular areas of lesions may be indicated by large-scale deactivation of immunosuppressive components such as IK and IDO, not only in the affected areas but also in the unaffected areas around the lesion. Recent studies have shown that increased IDO activity plays an important role in the activation of immunological tolerance in many Th1-mediated autoimmune diseases [18].
Genome-wide association analyses show that at a certain stage of AA development other pro-inflammatory factors and ligands that stimulate NK cells and induce the collapse of IP may become active. Although very few NK cells are observed around healthy anagen hair follicles, in AA lesions the follicles show visible clusters of CD56+ and NKG2D [19, 21]. In addition, hair follicles in AA overexpress MICA protein (MHC class I polypeptide-related sequence A), a key agonist of NKG2D, whereas MICA expression in healthy follicles is much lower. The conclusion that excessive NKG2D-mediated signalling may participate in the pathogenesis of AA is underscored by the genetic link between the disease and NKG2D-activating ligands of the MICA family, namely ULBP3. In fact, in AA the expression of ULBP3 protein is activated around the hair follicles of the lesion. It is now assumed that the characteristic infiltration of T cells around the hair follicle in the form of a «swarm of bees» is the result of activation of the ligand of the NK cell receptor NKG2D [21].
It is presumed that the neuropeptides calcitonin gene-related peptide (CGRP) and substance P (SP) may also have the capacity to provoke the collapse of IP [9]. CGRP has been reported to have an immunosuppressive effect in AA; its absence leads to vasoconstriction and hyperreactivity, including autoimmune reactions. SP is present in large amounts in AA lesions and causes degranulation of mast cells, which leads to the release of large amounts of TNF-α, known as a hair growth inhibitor. In addition, SP leads to the accumulation of CD8+ cells and stimulates the production of large amounts of IFN-γ, which stimulates the expression of MHC class I molecules in the lower part of the follicular epithelium, resulting in the presentation of follicular autoantigens to CD8+ cells and loss of IP. IFN-γ can also provoke the expression of MHC class II molecules by the follicular epithelium, leading to a second influx of CD4+ cells, which may assist the activity of CD8+ through the synthesis of pro-inflammatory cytokines [22, 24].
In the progressive stage of the disease, higher expression of adhesion molecules (ICAM-2 and ELAM-1), which bind leukocytes to endothelial cells and take part in the movement of leukocytes into the dermis, has been recorded in the perivascular and peribulbar zones of skin affected by alopecia areata. At the same time, the level of Fas ligand, a molecule known to induce apoptosis of activated T cells and neutrophils, is markedly reduced in the AA lesion. It is well known that Fas plays an important role in activating IP of the eye, brain and fetus [18, 19]. These facts were therefore accepted as evidence supporting the hypothesis of IP collapse in AA, leading to the subsequent attack of activated lymphocytes on the hair follicle.
As a rule, lymphocyte-mediated inflammation is triggered only after active presentation of an antigenic epitope with the assistance of several costimulatory ligands on antigen-presenting cells [16]. Infiltration of immune cells in AA may be associated with inadequate presentation of antigenic peptides derived from hair follicles. Catagen regression of hair follicles leads to large-scale apoptosis and tissue remodelling, in which immune cells usually seep in around the hair follicles [12, 25]. During this process the immune system may be constantly exposed to hair follicle antigens. An autoimmune reaction is not an all-or-nothing event; it is a progressive scale of responses with a threshold level above which overt autoimmune disease is observed [26].
Thus, the immune system is the main driving force of the pathological process in AA. Nevertheless, the main question, «What are the initial events leading to the development of AA?», has still not been resolved. At present, hypotheses of AA development focus mainly on the collapse of IP of hair follicles and the presentation of own autoantigens, which leads to activation and subsequent attack by T lymphocytes. Studies are under way to identify the autoantigens associated with the development of AA, but the exact nature of the antigenic epitopes or epitope that provoke the disease has yet to be established. Identifying the key signalling factors involved in the «switching on» and «switching off» of the hair life cycle in AA will contribute not only to understanding the potential mechanisms of the disease and the possible restoration of the IP of the hair follicle but, most importantly, to becoming the key to developing new, effective methods of treatment.
References
1. Олисова О. Ю. Современные представления об этиологии, патогенезе и лечении очаговой алопеции / О. Ю. Олисова, И. В. Верхогляд, И. П. Гостроверхова // Рос. журн. кожных и венерических болезней.— 2010.— No 1.— С. 48–52.
2. Сербина И. М. Цитокинопосредованные механизмы формирования гнездной алопеции / И. М. Сербина // Научные ведомости БелГУ. Серия: Медицина. Фармация.— 2014.— Т. 28, No 24 (195).— С. 32–38.
3. Etiological Study of Alopecia AREATA / G. Bharathi1, P. Venkata Ramana, K Sridevi, G. Usha // J. of Dental and Med. Sciences.— 2015.— Vol. 14, No 6.— P. 29–32.
4. Prevalence of psychological disorders in patients with alopecia areata in comparison with normal subjects / S. Aghaei, N. Saki, E. Daneshmand E. [et al.] // ISRN Dermatology.— 2014.— (304370).— P. 1–4.
5. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis / A. Alkhalifah, E. Wang, J. Shapiro [et al.] // J. of the Am. Academy of Dermatology.— 2010.— No 62.— P. 191–202.
6. The basic science of hair biology: what are the causal mechanisms for the disordered hair follicle? / T. Bretkopf, E. Wang, K. McElwee [et al.] // Dermatologic clinics.— 2013.— No 31.— P. 1–19.
7. Investigation of the inflammatory mechanisms in alopecia areata / E. D. Cetin, E. Savk, M. Uslu [et al.] // Am. J. Dermatopathol.— 2009.— No 31.— P. 53–60.
8. Gilhar A. Lymphocytes, neuropeptides, and genes involved in alopecia areata / A. Gilhar, R. Paus, R. Kalish // J. Clin. Invest.— 2007.— No 117.— P. 2019–2027.
9. Gilhar A. Collapse of Immune Privilege in Alopecia Areata: Coincidental or Substantial? / A. Gilhar // J. of Investigative Dermatology.— 2010.— No 130.— P. 2535–2537.
10. Gilhar A. Alopecia areata / A. Gilhar, A. Etzioni, R. Paus // The New England J. of medicine.— 2012.— No 366.— P. 1515–1525.
11. Harries M. J. The pathogenesis of primary cicatricial alopecias / M. J. Harrie, R. Paus // Am. J. Pathol.— 2010.— No 177.— P. 2152–2162.
12. Paus R. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives / R. Paus, M. Bertolini // J. Investig. Dermatol. Symp. Proc.— 2013.— No 6 (1).— P. 25–27.
13. Hordinsky M. Alopecia areata: an evidencebased treatment update / M. Hordinsky, A. Donati // American journal of clinical dermatology.— 2014.— No 15.— P. 231–246.
14. Ito T. Recent Advances in the Pathogenesis of Autoimmune Hair Loss Disease Alopecia Areata / T. Ito // Clin. and Developmental Immunology.— 2013.— ID348546.— P. 1–6.
15. Kasumagic-Halilovic E. Serum concentrations of interferongamma (IFN-g) in patients with alopecia areata: correlation with clinical type and duration of the disease / E. Kasumagic-Halilovic, A. Prohic, J. Karamehic // Med. Arhi.— 2010.— No 64.— P. 212–214.
16. Kang H. Hair follicles from alopecia areata patients exhibit alterations in immune privilege associated gene expression in advance of hair loss / H. Kang // The J. of investigative dermatology.— 2010.— No 130.— P. 1124–1136.
17. Trichohyalin is a potential major autoantigen in human alopecia areata / M. Leung, C. Sutton, D. Tobin [et al.] // J. of proteome research.— 2010.— No 9.— P. 5153–5163.
18. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(–) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model / K. J. McEl- wee, P. Freyschmidt-Paul, R. Hoffmann [et al.] // J. Invest. Dermatol.— 2005.— No 124.— P. 947–957.
19. Petukhova L. Genomewide association study in alopecia areata implicates both innate and adaptive immunity / L. Petukhova // Nature.— 2010.— No 466.— P. 113–117.
20. Probing the effects of stress mediators on the human hair follicle: substance P holds central position / E. M. Peters, S. Liotiri, E. Bodo [et al.] // Am. J. Pathol.— 2007.— No 171.— P. 1872–1886.
21. Schneider M. R. The hair follicle as a dynamic miniorgan / M. R. Schneider, R. Schmidt-Ullrich, R. Paus // Curr. Biol.— 2009.— No 19.— P. 132–142.
22. D’Ovidio R. Alopecia Areata: news on diagnosis, pathogenesis and treatment / R. D’Ovidio // G. Ital. Dermatol. Venereol.— 2014.— No 149.— P. 25–45.
23. Tembhre M. K. T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areatа / M. K. Tembhre, V. K. Sharma // Br. J. Dermatol.— 2013.— Vol. 169.— P. 543–548.
24. Wang E. Etiopathogenesis of alopecia areata: Why do our patients get it? / E. Wang, J. McElwee // Dermatologic Therapy.— 2011.— Vol.24.— P. 337–347.
25. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition / L. Xing, Z. Dai, A. Jabbari [et al.] // Nature medicine.— 2014.— P. 1043–1049.
26. Hordinsky M. Overview of Alopecia Areata / M. Hordinsky // J. of Investigative Dermatology Symposium Proceedings.— 2013.— Vol. 16, No 1.— P. S13–S15.